NeuroPace (NPCE) EPS (Diluted) Growth (3y) (2023 - 2026)
NeuroPace (NPCE) EPS (Diluted) Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.74 Bn | 176.45 Bn | 6.27 Bn | -6.43% |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn | 7.66% |
| 3 | Medtronic | 108.48 Bn | 99.26 Bn | 6.41 Bn | 3.09% |
| 4 | Boston Scientific | 68.51 Bn | 67.05 Bn | 3.61 Bn | 62.91% |
| 5 | Edwards Lifesciences | 48.32 Bn | 44.65 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.41 Bn | 27.29 Bn | 750.30 Mn | 63.42% |
| 7 | GE HealthCare Technologies | 28.23 Bn | 25.95 Bn | 1.98 Bn | 29.56% |
| 8 | Smith & Nephew | 26.90 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 24.47 Bn | 21.35 Bn | 2.07 Bn | 30.57% |
| 10 | NeuroPace | 518.90 Mn | 464.92 Mn | 18.05 Mn | -19.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.60% |
| Dec 31, 2025 | 35.92% |
| Sep 30, 2025 | 31.71% |
| Jun 30, 2025 | -9.11% |
| Mar 31, 2025 | 23.85% |
| Dec 31, 2024 | 36.46% |
| Sep 30, 2024 | 16.27% |
| Jun 30, 2024 | 9.90% |
| Mar 31, 2024 | 75.30% |
| Dec 31, 2023 | 74.68% |
| Sep 30, 2023 | 75.62% |
| Jun 30, 2023 | 78.37% |
| Mar 31, 2023 | 79.11% |